 Cabaletta Bio, Inc. Nasdaq: CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track Designation for DSG3-CAART Desmoglein 3 Chimeric AutoAntibody Receptor T cells, the Companys lead product candidate for treatment of mucosal pemphigus vulgaris mPV, for improving healing of mucosal blisters in patients with mPV. 